Open AccessFGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
Author(s) -
Chen Hong,
Jianping Weng,
Tao Zhou,
Xia Wang,
Jing Cai
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s364566
Subject(s) - medicine , adenocarcinoma , lung cancer , fibroblast growth factor receptor , fusion gene , lung , chemotherapy , oncology , fibroblast growth factor , adenocarcinoma of the lung , cancer research , cancer , gene , receptor , biology , biochemistry
Fibroblast growth factor receptor (FGFR) fusions in non-small cell lung cancer (NSCLC) are small genomic events. At present, there is no standard treatment strategy for patients with NSCLC carrying an FGFR fusion.